UZH

UNIVERSITAET ZUERICH (UZH)

http://www.uzh.ch

Founded in 1833, the University of Zurich is Switzerland’s largest university, with a current enrolment of over 26,000 students. UZH is made up of seven faculties covering approximately 100 different subject areas. As a member of the “League of European Research Universities” (LERU), UZH is one of Europe’s most prestigious research institutions. The University’s international standing is reflected in the many renowned academic distinctions conferred upon its members over the years, including twelve Nobel Prizes. Furthermore, the close association between medical research and the clinical services provided in the five university hospitals translates into first-rate medical care for the general population.

Most of the ATECT will be carried out at the Institute of experimental Immunology at the University of Zurich (http://www.immunology.uzh.ch/). This institute was founded 1992 from parts of the Institute of Pathology (Experimental Pathology directed by Prof. G. Zbinden) and the Institute of Immunology and Virology (directed by Prof. J. Lindenmann, who co-discovered interferon with Dr. Alick Isaacs in 1957). Until 2008 the Institute was codirected by Prof. Hans Hengartner and Prof. Rolf Zinkernagel, who was awarded the Nobel Prize of Physiology and Medicine 1996 together “for their discoveries concerning the specificity of the cell mediated immune defence”.

Dr. Becher is chairman of the Institute which consists of 6 research groups and more than 60 researchers. The institute is endowed with close to 1000m2 of lab and office space and a vivarium for up to 6000 mice. It is equipped with state of the art research equipment for molecular and cellular biology, flow cytometry and microscopy.

The primary expertise of the Becher-lab is cytokine biology and cellular immunology. The Becher-team has extensive experience in a variety of immunological methods surrounding in vivo models of autoimmune disease and cancer. The group partakes in several FP7 funded activities. Partner 3 (UZH) will provide and share the expertise in in vivo models of cancer, multiparameter cytokine analysis, flow cytometry, microscopy/pathology, gene-targeting, bioluminescence in vivo imaging.

Advertisements